Search

Your search keyword '"Zachary L. Skidmore"' showing total 128 results

Search Constraints

Start Over You searched for: Author "Zachary L. Skidmore" Remove constraint Author: "Zachary L. Skidmore"
128 results on '"Zachary L. Skidmore"'

Search Results

1. pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection

2. Cancer treatment monitoring using cell-free DNA fragmentomes

3. Single-cell T-cell receptor repertoire profiling in dogs

4. Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer

5. Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer

6. Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer

7. Genomic landscape and gene expression profiles of feline oral squamous cell carcinoma

8. Integrative genomic analysis reveals low T-cell infiltration as the primary feature of tobacco use in HPV-positive oropharyngeal cancer

9. The prognostic effects of somatic mutations in ER-positive breast cancer

10. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

12. Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas

13. Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer

14. CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase

15. Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers

16. Supplementary Figure from Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis

17. Supplementary Table from Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis

18. Data from Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis

19. Supplementary Figure 4 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

20. Supplementary Figure 3 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

21. Data from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

24. Supplementary Figure 5 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

25. Data from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

26. Supplementary Tables S1 and S2 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

27. Supplementary Data from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

28. Supplementary Table S3 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

29. Supplementary Figure Legends from A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer

32. Supplementary Figure 9 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

33. Data from Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas

34. Supplementary Figure 2 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

35. Supplementary Figure S2 from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

36. Data from A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer

40. Supplementary Figure 7 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

41. Supplementary Appendix from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

42. Supplementary Figure 10 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

44. Supplementary table S3 from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

46. Supplementary Tables from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

47. Supplementary Figure 6 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

48. Supplementary Figure 8 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

49. Data from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

50. Supplementary Tables and Supplementary Figure Legend from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

Catalog

Books, media, physical & digital resources